This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Jimin Kexin Pharmaceutical fined by China's SAMR for failure to notify Nanjing Hencer deal

( August 5, 2020, 01:44 GMT | Official Statement) -- MLex Summary: Jiangxi Jimin Kexin Pharmaceutical Industry Investment has been fined 300,000 yuan ($42,970) by China’s State Administration for Market Regulation for failing to notify its acquisition of an 83.35 percent stake in Nanjing Hencer Pharmaceutical. In a penalty decision dated June 25, 2020, but released today, the regulator said the deal reached the notification threshold, but it had no anticompetitive impact. SAMR started an investigation into the case in July last year.The statement follows and the penalty decision is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections